Department of Gastroenterology, The Second Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Center of Gut Microbiota, The Second Hospital of Anhui Medical University, Hefei, Anhui Province, China.
Eur J Public Health. 2023 Apr 1;33(2):336-341. doi: 10.1093/eurpub/ckad032.
Fecal DNA and occult blood testing have been gradually developed for colorectal cancer (CRC) screening. Comparison of different testing strategies for these methods in CRC screening is in urgent need. This study aims to examine the efficacy of different testing strategies including multi-target fecal DNA testing, qualitative and quantitative fecal immunoassay tests (FITs).
Fecal samples were collected from patients diagnosed by colonoscopy. Tests using fecal DNA, quantitative FIT or qualitative FIT were performed on same fecal samples. Efficiency of different testing strategies within different populations was investigated.
For high-risk populations (CRC and advanced adenoma), the positive rate of the three methods alone was 74.3-80%; the positive predictive values (PPVs) ranged from 37.3% to 77.8%, and the negative predictive values (NPVs) ranged from 86.3% to 92.2%. For combined testing strategies, the positive rate was 71.4-88.6%, PPVs ranged from 38.3% to 86.2%, and NPVs ranged from 89.6% to 92.9%. Parallel fecal multi-target DNA test and quantitative FIT appears to be superior when using a combined testing strategy. For the normal population, no significant difference was identified in efficacy between these methods when used alone and in combination.
Single testing strategy among the three methods is more suitable for the general population screening, and the combined testing strategy is more suitable for high-risk populations screening. The use of different combination strategies may have superiority in CRC high-risk population screening, but cannot conclude significant differences which may be attributed to the small sample size, large samples controlled trials are needed.
粪便 DNA 和粪便潜血检测已逐渐应用于结直肠癌(CRC)筛查。目前急需比较这些方法在 CRC 筛查中的不同检测策略的效果。本研究旨在评估不同检测策略的效果,包括多靶点粪便 DNA 检测、定性和定量粪便免疫检测(FIT)。
收集经结肠镜诊断的患者粪便标本。对同一份粪便标本同时进行粪便 DNA、定量 FIT 和定性 FIT 检测。研究了不同人群中不同检测策略的效率。
对于高危人群(CRC 和高级腺瘤),三种方法单独检测的阳性率为 74.3-80%;阳性预测值(PPV)范围为 37.3%-77.8%,阴性预测值(NPV)范围为 86.3%-92.2%。对于联合检测策略,阳性率为 71.4-88.6%,PPV 范围为 38.3%-86.2%,NPV 范围为 89.6%-92.9%。当使用联合检测策略时,平行粪便多靶点 DNA 检测和定量 FIT 似乎更优。对于普通人群,三种方法单独和联合使用时,效果没有显著差异。
三种方法中,单一检测策略更适用于普通人群筛查,而联合检测策略更适用于高危人群筛查。不同联合策略的使用可能在 CRC 高危人群筛查中具有优势,但由于样本量小,不能得出显著差异的结论,需要进行更大样本量的对照试验。